Table 4.
The comparisons of the demographic and clinical characteristics between patients who developed KD during epidemic and non-epidemic periods in the years of large HFMD epidemics*a.
| Characteristics | Epidemic period*b n = 50 |
Non-epidemic period*c n = 229 |
P-value |
|---|---|---|---|
| Age, months, median (range) | 23.5 (3–87) | 24.0 (1–143) | 0.80 |
| Gender, n, %male | 29 (58.0) | 140 (61.1) | 0.68 |
| Days of illness at the initial IVIG therapy, median (range) | 5 (3–10) | 5 (1–10) | 0.37 |
| White blood cell counts, 109/L, median (range) | 13.3 (6.3–23.2) | 13.5 (1.1–33.0) | 0.59 |
| Neutrophil, %, median (range) | 67.4 (20.5–94.2) | 65.3 (5–92) | 0.71 |
| Platelet counts, ×109/L, median (range) | 329 (129–824) | 299 (74–1,299) | 0.20 |
| Serum aspartate aminotransferase level, IU/L, median (range) | 35.5 (21–4,489) | 37.0 (4.1–874) | 0.63 |
| Serum sodium level, mEq/L, median (range) | 135 (128–144) | 135 (125–143) | 0.51 |
| Serum C-reactive protein level, mg/L, median (range) | 58 (17–279) | 68 (0.7–207) | 0.27 |
| Kobayashi score, median (range) | 3 (0–10) | 3 (0–10) | 0.15 |
| Patients with resistance to the initial IVIG therapy, n (%) | 7 (14) | 43 (18.7) | 0.42 |
| Patients with CAAs, n (%) | 2 (4.0) | 10 (3.6) | 0.79 |
| Fatal case, n (%) | 0 (0) | 0 (0) | N.D. |
*a
The years with large HFMD epidemics indicate 2011 and 2013.
*b
Epidemic period indicates July and August.
*c
Non-epidemic period indicated from January to June and from September to December.
HFMD, hand-foot-mouth disease; KD, Kawasaki disease; IVIG, intravenous immunoglobulin; CAA, coronary artery abnormality; N.D., no data.